Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
6.73
-0.21 (-3.03%)
Mar 27, 2026, 4:00 PM EDT - Market closed
Fulcrum Therapeutics Employees
Fulcrum Therapeutics had 55 employees as of December 31, 2025. The number of employees increased by 10 or 22.22% compared to the previous year.
Employees
55
Change (1Y)
10
Growth (1Y)
22.22%
Revenue / Employee
n/a
Profits / Employee
-$1,361,455
Market Cap
448.22M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 55 | 10 | 22.22% |
| Dec 31, 2024 | 45 | -31 | -40.79% |
| Dec 31, 2023 | 76 | -13 | -14.61% |
| Dec 31, 2022 | 89 | -15 | -14.42% |
| Dec 31, 2021 | 104 | 31 | 42.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Maravai LifeSciences Holdings | 435 |
| Lyell Immunopharma | 300 |
| Rigel Pharmaceuticals | 174 |
| Entrada Therapeutics | 152 |
| Absci | 140 |
| Verastem | 102 |
| enGene Holdings | 82 |
| Assembly Biosciences | 73 |
FULC News
- 9 days ago - MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease - GlobeNewsWire
- 22 days ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion - Seeking Alpha
- 4 weeks ago - Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 - GlobeNewsWire
- 4 weeks ago - Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire
- 5 weeks ago - Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire